Agios Pharmaceuticals (MEX:AGIO) Cyclically Adjusted Book per Share: MXN681.98 (As of Mar. 2026)


MEX:AGIO Agios Pharmaceuticals Inc MEX:AGIO
44 GF Score
Price MXN1,222.00
GF Value MXN2,772.90
! 3 Warning Signs
View Full Analysis

What is Agios Pharmaceuticals Cyclically Adjusted Book per Share?

Agios Pharmaceuticals MEX:AGIO 44 Cyclically Adjusted Book per Share is MXN681.98 as of Mar. 2026. GuruFocus rates MEX:AGIO with a GF Score™ of 44/100 and a GF Value™ of MXN2,772.90. The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Agios Pharmaceuticals's adjusted book value per share for the three months ended in Mar. 2026 was MXN738.734. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is MXN681.98 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Agios Pharmaceuticals's average Cyclically Adjusted Book Growth Rate was 11.30% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 10.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Agios Pharmaceuticals was 14.10% per year. The lowest was 10.80% per year. And the median was 12.45% per year.

As of today (2026-07-02), Agios Pharmaceuticals's current stock price is MXN1222.00. Agios Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was MXN681.98. Agios Pharmaceuticals's Cyclically Adjusted PB Ratio of today is 1.79.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Agios Pharmaceuticals was 3.81. The lowest was 1.34. And the median was 1.95.


Agios Pharmaceuticals  (MEX:AGIO) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Agios Pharmaceuticals's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=1222.00/681.98
=1.79

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Agios Pharmaceuticals was 3.81. The lowest was 1.34. And the median was 1.95.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Agios Pharmaceuticals Cyclically Adjusted Book per Share Related Terms


Agios Pharmaceuticals Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Agios Pharmaceuticals's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Agios Pharmaceuticals Cyclically Adjusted Book per Share Chart

Agios Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 240.54 274.75 267.31 613.60 800.00

Agios Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 707.34 636.72 537.63 800.00 681.98

MEX:AGIO vs ABCL, KOD, IMNM: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Agios Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Agios Pharmaceuticals Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Agios Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Agios Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.


MEX:AGIO
44GF Score
Agios Pharmaceuticals Inc MEX:AGIO
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Agios Pharmaceuticals Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Agios Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=738.734/330.2130*330.2130
=738.734

Current CPI (Mar. 2026) = 330.2130.

Agios Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201606 140.575 241.018 192.598
201609 184.753 241.428 252.696
201612 175.108 241.432 239.500
201703 136.556 243.801 184.956
201706 190.306 244.955 256.543
201709 167.902 246.819 224.632
201712 151.040 246.524 202.314
201803 273.292 249.554 361.623
201806 279.190 251.989 365.858
201809 244.461 252.439 319.777
201812 231.879 251.233 304.775
201903 205.110 254.202 266.442
201906 174.167 256.143 224.532
201909 150.314 256.759 193.316
201912 176.611 256.974 226.946
202003 213.142 258.115 272.678
202006 186.660 257.797 239.093
202009 153.381 260.280 194.592
202012 114.683 260.474 145.388
202103 672.455 264.877 838.326
202106 572.090 271.696 695.305
202109 524.154 274.310 630.974
202112 487.790 278.802 577.738
202203 438.907 287.504 504.107
202206 412.552 296.311 459.754
202209 384.817 296.808 428.127
202212 389.925 296.797 433.826
202303 336.389 301.836 368.014
202306 296.596 305.109 321.000
202309 276.427 307.789 296.566
202312 246.071 306.746 264.896
202403 217.549 312.332 230.004
202406 212.758 314.175 223.619
202409 561.707 315.301 588.273
202412 562.281 315.605 588.307
202503 518.295 319.799 535.173
202506 444.315 322.561 454.855
202509 404.255 324.800 410.992
202512 367.549 324.054 374.535
202603 738.734 330.213 738.734

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of MXN681.98 mean?
Agios Pharmaceuticals (MEX:AGIO) has a Cyclically Adjusted Book per Share of MXN681.98 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Agios Pharmaceuticals and its competitors.
Is Agios Pharmaceuticals' Cyclically Adjusted Book per Share too high?
Agios Pharmaceuticals' current Cyclically Adjusted Book per Share is MXN681.98. Overall, Agios Pharmaceuticals has a GF Score™ of 44/100, reflecting its overall financial health beyond just this single metric.
How does Agios Pharmaceuticals' Cyclically Adjusted Book per Share compare to ABCL and KOD?
Agios Pharmaceuticals' Cyclically Adjusted Book per Share of MXN681.98 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Agios Pharmaceuticals and its competitors. Agios Pharmaceuticals's current Cyclically Adjusted Book per Share is MXN681.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Agios Pharmaceuticals stock overvalued right now?
Agios Pharmaceuticals (MEX:AGIO) has a current Cyclically Adjusted Book per Share of MXN681.98. The stock's GF Value™ is MXN2,772.90, compared to a current price of MXN1,222.00 — trading 55.9% below its estimated fair value. The current Cyclically Adjusted Book per Share is MXN681.98. Agios Pharmaceuticals' overall GF Score™ is 44/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Agios Pharmaceuticals (MEX:AGIO), the current Cyclically Adjusted Book per Share is MXN681.98 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Agios Pharmaceuticals (MEX:AGIO) Overvalued in 2026?

Based on GuruFocus' analysis, Agios Pharmaceuticals stock appears to be undervalued. The current stock price of MXN1,222.00 is trading 55.9% below its estimated GF Value™ of MXN2,772.90.

Key valuation signals for MEX:AGIO:

  • Cyclically Adjusted Book per Share: MXN681.98
  • GF Value™: MXN2,772.90 vs. price of MXN1,222.00 (55.9% below fair value)
  • GF Score™: 44/100 with 3 warning signs

No single metric tells the full story. See the MEX:AGIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Agios Pharmaceuticals Business Description

Other Exchanges AGIO:USA0HB0:UK8AP:Germany
Address 88 Sidney Street, Cambridge, MA, USA, 02139
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.
44GF Score

Get the complete analysis for MEX:AGIO

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN1,222.00
Price
MXN2,772.90
GF Value